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ABSTRACT
Enlimomab, an anti-interleukin-2 receptor (anti-IL-2R) monoclonal antibody, may be useful in the treatment
of steroid-refractory acute graft-versus-host disease (aGVHD) by inhibiting 1 of its putative immunopatho-
genic pathways. We retrospectively analyzed 40 consecutive patients who received enlimomab as salvage
treatment for steroid refractory aGVHD at a single institution between June 1999 and December 2004.
Enlimomab was given intravenously at a dose of 11 mg/d for 3 consecutive days, followed by 5.5 mg/d for 7
consecutive days and then 5.5 mg every other day for 5 doses. No infusion-related side effects were noted.
Twenty-three patients (58%) responded, including 15 (38%) complete and 8 (20%) partial responses. Median
overall survival was 294 days (58-996 days) for responders versus 14 days for nonresponders (P < .001), with
a 1 year probability of 59% vs 0% for overall survival (P < .0001). Patients without gastrointestinal (GI)
involvement showed a higher response rate (100% versus 50% for those without versus with GI involvement,
P  .03) In addition, patients who showed some response by day 15 had a higher overall survival (73  12% vs
24  12%, respectively, P  .02). The results of this study suggest that enlimomab may be an effective salvage
therapy for patients with steroid-refractory aGVHD, particularly for those without GI disease, and supports
further studies with this agent in prospective controlled trials.
© 2006 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Refractory acute graft-versus-host disease (aGVHD)
emains an important cause of morbidity and mortality
fter allogeneic hematopoietic stem cell transplantation.
teroids are ﬁrst-line treatment for aGVHD [1], but
hey fail to obtain a good response in up to 50% of
atients [2,3]. Antithymocyte globulin (ATG) has been
idely used in steroid refractory aGVHD [4], but the
esults with this second-line therapy are poor, mainly
ue to high mortality from opportunistic infections.
ther salvage regimens, such as mycophenolate mofetil
ose Luis Piñana and David Valcárcel contributed equally to the elabo-
Tation of this study.MMF) and tacrolimus, also seem to have limited efﬁ-
acy [5,6].
With the recent advances in the understanding of
he immune-pathophysiology of aGVHD it has been
ossible to identify several potential new therapeutics
argets [7]. Monoclonal-antibodies against cytokines
uch as interleukin (IL)-2 and IL-1, tumor necrosis fac-
or , and interferon  are being used to block T cell
ctivation and as a consequence to prevent or treat
VHD [1,8]. Treatment of aGVHD using anti-IL-2
eceptor (anti-IL-2R) is justiﬁed by the fact that this
eceptor is crucial in the effector phase of aGHVD
7-9]. IL-2 promotes the expansion and differentiation
f T cells [7]. Therefore, blockage of IL-2-induced
cell activation may prevent or revert aGVHD.
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J. L. Pin˜ana et al.1136IL-2R is a heterodimeric molecule with 3 polypep-
ide chain subunits (, , ) [10]. Most T cells express 2
ubunits, conforming intermediate-afﬁnity IL-2R. Ex-
ression of the -subunit (CD25) conforms the high-
fﬁnity receptor for IL-2. This high-afﬁnity IL-2R is
xpressed on activated T cells, whereas resting T cells
ack this receptor. Selective inhibition of activated T cells
ould theoretically favor immunologic recovery by acti-
ating T cells that do not express CD25 by blocking
L-2.
Enlimomab is a murine immunoglobulin G1
onoclonal antibody directed against the -chain of
L-2R. Anti-Il-2R has shown beneﬁcial effects in the
reatment of aGVHD [11-14]. In contrast, there are
lso experiences showing a poor efﬁcacy of anti-IL-2R
s prevention or treatment for this complication [15-
7]. These discrepancies may be explained in part by
ifferent patient selections and by the fact that there
re several anti-IL-2R antibodies with different phar-
acokinetic proﬁles and possibly different afﬁnities to
L-2R and soluble IL-2R, which may lead to variable
egrees of inactivation and to different results.
During a 5-year period, we used an anti-IL-2R
ntibody, enlimomab, as treatment for steroid-refrac-
ory aGVHD and for treatment of aGVHD resistant
o steroids and ATG.
ETHODS
atients
In this study we retrospectively analyze all 40
onsecutive patients who received enlimomab as sal-
age therapy for aGVHD between June 1999 and
ecember 2004. All patients gave their written in-
ormed consent and the drug was administered as
ompassionate use after approval from our institu-
ional and national health authorities.
VHD Diagnosis and Response Assessment
Diagnosis of aGVHD was based mainly on classic
linical presentation with conﬁrmatory pathologic
ndings in all but 1 patient.
Resistant aGVHD was deﬁned as disease progres-
ion in the ﬁrst 3 days or if there was no improvement
fter 7 days of initial or second-line treatment. Max-
mum staging of aGVHD was deﬁned according to
stablished criteria [18] and was assessed the day be-
ore beginning enlimomab.
Response to treatment was deﬁned as follows:
omplete response (CR) was the clinical and labora-
ory disappearance of aGVHD features, partial re-
ponse (PR) was a decrease of 1 grade in overall
tage of aGVHD, and no response included stable and
rogressive disease. Those patients who showed im-
rovement in 1 organ but whose disease progressed in 41 other organ were considered to show progression
f aGVHD.
herapy
Patients received enlimomab according to the
anufacturer’s instructions; the drug was adminis-
rated intravenously at 11 mg/d for 3 days, 5.5 mg/d
or 7 days, and 5.5 mg every other day for 5 doses.
hirty patients received 1 course of enlimomab, 8
atients received 2 courses, and 2 patients received 3
ourses due to absence of response or relapse after
esponse to the ﬁrst course of the drug. Cyclosporine
(CsA) and/or MMF was maintained during enli-
omab treatment, but those patients who were on
TG treatment stopped this drug before enlimomab
reatment. After enlimomab was started, steroids were
apered, although most patients continued with low
oses of steroids (0.2-0.5 mg/kg per day of prednisone
r an equivalent) while on enlimomab.
tatistical Analysis
Differences in response rate according to the or-
ans involved, number of salvage therapies, cycles of
nlimomab, and onset of aGVHD were assessed by
hi-square test and Student t test. Survival was esti-
ated by the Kaplan-Meier method and comparisons
f actuarial curves were made by log-rank and Taron-
are tests. In the comparison of responders with
onresponders and the comparison of day-15 re-
ponders, we excluded those patients who died before
ay 15 after the start of enlimomab. Nonrelapse mor-
ality was calculated by using cumulative incidence,
ith relapse of neoplastic disorders as a competitive
ariable. Follow-up and overall survival (OS) were
alculated since the start of enlimomab treatment.
esponse was analyzed with respect to the ﬁrst cycle
f enlimomab even in those patients who received 1
ycle of the drug.
ESULTS
atient Characteristics
The characteristics of the 40 patients who were
reated are listed in Tables 1 and 2.
All patients showed a clinical picture compatible
ith aGVHD and all had histopathologic ﬁndings
ompatible with aGVHD in the organs biopsied. Only
patient had no histologic proof of aGVHD, but he
eveloped a typical rash plus liver abnormalities. The
kin rapidly improved with steroids but the liver dis-
ase progressed, and the liver subsequently showed
R with enlimomab.
There were 29 men (73%) and 11 women (27%),
ith a median age of 47 years (range, 17-63 years).
ollow-up for the entire group was 58 days (range,
-996 days) and that for survivors was 351 days (range,
Table 1. Clinical Characteristic of Patients Who Received Enlimomab as Salvage Therapy for Acute GVHD
Pt.
N
Age
Sex Disea DO
Cond
Reg
GVHD
Prophylaxis
Onset
GVHD
(d) Grade
Affected
Organ Prior Therapies
Dehy GVHD-
Inolimomab
(d)* N°Cycles Resp
Surv
(days)
Relapse of
aGVHD/
Chronic
GVHD
Cause
of Death
1 34/F AA MMU SC CsA, MTX, ATG 14 III S, GI PDN  ATG‡ 74 1 NR 24 –/– aGVHD
2 34/F AA MU SC MTX, Tc, ATG 13 IV S, L, GI PDN  ATG† 21 1 NR 4 –/– IFI
3 48/M CLL IS SC CsA 21 IV S, L, GI PDN  MMF 39 1 NR 8 –/– aGVHD
4 47/M NHL IS RIC CsA, MTX 50 III S, L, GI PDN  MMF  ATG 4 1 NR 19 –/– aGVHD
5 35/F ALL IS SC CsA, MTX 88 IV L, GI PDN  ATG 21 1 PR 24 No/Ext cGVHD
6 38/F CML MMU SC CsA, MTX 10 III S, L, GI PDN  ATG 24 1 CR 65 Yes/No aGVHD
7 54/F ALL IS SC CsA, MTX 33 IV S, L, GI PDN  MMF  ATG† 23 1 NR 8 –/– aGVHD
8 62/F CLL IS RIC CsA, MTX 25 III S, L, GI PDN  ATG† 19 1 CR 191 No/Ext cGVHD
9 54/F CLL IS RIC CsA, MTX 40 III S, L, GI PDN  ATG 29 1 CR 996 No/Ext Alive
10 47/M ST MMR SC CsA, MMF 17 III S, GI PDN 8 1 NR 4 –/– aGVHD
11 49/F NHL IS RIC CsA, MTX 34 IV S, L, GI PDN  ATG 22 1 NR 14 –/– RSV
12 49/M AML IS SC CsA 75 IV L, GI PDN  MMF 43 1 NR 27 –/– aGVHD
13 61/M CLL IS RIC CsA, MTX 36 III L PDN  MMF  ATG§ 48 1 PR 31 Yes/– aGVHD
14 47/M CML IS RIC CsA, MTX 50 III GI PDN  MMF 15 1 NR 34 –/– aGVHD
15 61/M NHL IS RIC CsA, MTX 16 II L, GI PDN 64 1 CR 58 Yes/No CMV
16 31/M CML MU SC CsA, MTX 12 IV S, L, GI PDN  MMF  ATG 31 2 CR 483 No/Lim Alive
17 32/M MDS IS SC CsA, MTX 16 IV S, L, GI PDN  ATG 22 1 CR 549 No/Lim Alive
18 37/M ST IS RIC CsA, MTX 18 III S, L, GI PDN  MMF  ATG 25 2 CR 594 No/Ext Alive
19 48/M CML IS RIC CsA, MTX 25 III S, GI PDN  ATG 36 1 CR 603 No/Lim Alive
20 47/M AML MMU SC CsA, MTX, ATG 39 IV S, L, GI PDN  MMF 4 1 NR 13 –/– aGVHD
21 63/M AML IS RIC CsA, MTX 22 III S, GI PDN  MMF  ATG 64 1 NR 13 –/– aGVHD
22 49/F MM IS RIC CsA, PDN 28 III L, GI PDN  MMF  ATG† 14 2 NR 23 –/– CMV
23 23/M AML MU RIC CsA, PDN 33 III S, GI PDN  MMF 91 1 PR 91 No/Lim cGVHD
24 37/M CML MMU SC MTX, PDN, ATG 69 III L PDN 79 1 CR 221 No/Lim Alive
25 59/M AML IS SC CsA 29 III S, L PDN  ATG 80 2 CR 233 –/Ext cGVHD
26 57/F MM IS RIC CsA, MTX 30 II L, GI PDN  MMF  ATG 22 1 NR 4 –/– CMV
27 60/M PTL MU RIC CsA, MMF 24 III S, GI PDN  MMF 17 3 NR 52 –/– aGVHD
28 30/M HD MMU RIC CsA, MMF, ATG 57 IV GI PDN  MMF 6 1 PR 63 –/Ext Alive
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; F, female; M, male; AA, aplastic anemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin
lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; ST, solid tumor; MDS, myelodysplastic syndrome; MM, multiple myeloma; PTL,
prolymphocytic T cell leukemia; HD, Hodgkin disease; IS, identical sibling donor; MMU, mismatched unrelated donor; MMR, mismatched related donor; MU, matched unrelated donor; SC,
standard conditioning; RIC, reduced intensity conditioning; S, skin; L, liver; GI, gastrointestinal; PDN, prednisone; MMF, mycophenolate mofetil; CsA, cyclosporine A; MTX, methotrexate; Tc,
tacrolimus; NR, no response; CR, complete response; PR, partial response; Ext, extensive; Lim, limited; IFI, invasive fungal infection; RSV, respiratory syncytial virus.
*Calculated from onset of aGVHD.
†Not on CsA.
‡With Tc.
§With sirolimus.
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J. L. Pin˜ana et al.11388-996 days). Twenty-seven patients (68%) received an
LA-identical sibling graft, 7 (18%) a mismatched un-
elated transplant, 5 (12%) a matched unrelated trans-
lant, and 1 (2%) a transplant from a mismatched related
onor. GVHD prophylaxis was based on CsA (1 mg/kg
very 12 hours adjusted for levels between 200 and 300
mol/L) in 38 patients: 3 with CsA alone, 28 with CsA
nd a short course of methotrexate (10 mg/m2 on days
1, 3, 6; associated with ATG 10 mg/kg in 3 of
hem), 2 with CsA and prednisone, and 5 with CsA
nd MMF (3 g/d in 3 doses) in 2 of them with ATG.
wo patients received a short course of methotrexate
ith ATG, 1 with prednisone and the other with
acrolimus.
Six patients (15%) received enlimomab as second-
ine treatment and 34 (85%) as third- or fourth-line
reatment. Treatments used before enlimomab are
isted in Table 1. Enlimomab was initiated after a
edian of 21 days (range, 4-91 days) from the onset of
GVHD.
VHD Characteristics
Acute GVHD was grade II in 2 patients (5%),
rade III in 22 patients (55%), and grade IV in 16
atients (40%). Mean onset of aGVHD was day 32
range, 10-173 days). Two patients who underwent a
educed intensity conditioning regimen developed
GVHD after day 100. Nevertheless, we considered
GVHD based on clinical manifestations and biopsy
able 2. Patient Characteristics
Characteristics
Responders
(n  23)
Nonresponders
(n  17) P
atient age (y) 43.48 (21-62) 46.59 (17-63) .43
ale sex 18 (78%) 11 (65%) .47
umber of transplants
1 18 (78%) 10 (59%) .296
2 5 (22%) 7 (41%)
IC regimens 13 (57%) 10 (59%) 1
BI (yes) 10 (43%) 4 (24%) .315
LA matching (yes) 7 (30%) 5 (29%) 1
onor age (y) 60.44 (0-74) 45.15 (0-61) .42
emale sex donor 8 (35%) 10 (58%) .26
D34 cell dose 
106/kg 6.17 (3-16) 5.54 (1.96-9.10) .513
cute GVHD grade
II 1 (4%) 1 (6%) .315
III 15 (65%) 7 (41%)
IV 7 (30%) 9 (53%)
rior ATG 11 (48%) 9 (53%) 1
eukocyte count before
enlimomab  109/L 4.8  2.8 5.6  4.4 .45
ymphocyte count
before enlimomab 
109/L 0.46  0.32 0.22  0.22 .007
IC indicates reduced intensity conditioning; TBI, total body irra-
diation; GVHD, graft-versus-host disease; ATG, antithymocyte
globulin.ecause it is now well recognized that aGVHD fea- Aures in reduced intensity conditioning allogeneic
tem cell transplantation can begin after the classic day
100.
Table 1 lists patient characteristics. Brieﬂy, at the
eginning of enlimomab treatment, the skin was in-
olved in 30 patients (4 patients with stage 1, 18 with
tage 2, 7 with stage 3, and 1 with stage 4). Liver
nvolvement was present in 29 patients (5 patients with
tage 1, 9 with stage 2, 10 with stage 3, and 5 with stage
). Gastrointestinal (GI) involvement was present in 34
atients (6 patients with stage 1, 11 with stage 2, 9
ith stage 3, and 8 with stage 4). Six patients showed
o GI involvement, 3 showed combined liver and skin
nvolvement, and 3 had only liver involvement when
herapy with enlimomab was begun.
esponse to Therapy
Response to enlimomab was observed in 23 pa-
ients (58%). Fifteen patients (38%) achieved a CR (1
atient with grade II GVHD, 10 with grade III, and
with grade IV). Eight patients (20%) obtained a
R (5 with grade III and 3 with grade IV). Eight
atients (20%) had stable disease and 9 (22%) had
rogression of aGVHD. Relapse of aGVHD was
bserved in 5 (22%) of 23 responders (2 with CR
nd 3 with PR). Sixteen of 23 responders (70%)
mproved in the ﬁrst 15 days and 7 (30%) improved
hereafter (Table 3).
Achievement of CR was time dependent. On day
5, 14 of 16 responders (88%) were in PR and 2 were
n CR; on day 30, 12 of 20 responding patients (60%)
ad a PR and 8 (40%) a CR; on day 60 after enli-
omab, 14 of 20 responders (70%) showed CR and 6
30%) showed PR. More responses were observed in
atients who received enlimomab as second-line treat-
ent (after steroid failure, n  6) than in those who
eceived it as third-line (n  24) or fourth-line (n 
0) therapy after failure of ATG or MMF (83% versus
0% versus 36%, respectively; P  .052).
able 3. Response according to Patient Characteristics
Variable Response, n (%) P
ine of treatment, n (%)
Second, 6 (15) 5 (83) .052
Third, 23 (57) 14 (60)
More than third, 11 (28) 4 (36)
iagnosis, n (%)
Acute leukemia, 12 (30) 8 (67) .505
Other, 28 (70) 15 (54)
ourses of enlimomab, n (%)
1 cycle, 30 (75) 15 (50) .086
>1 cycle, 10 (25) 8 (80)
rior ATG, n (%)
Yes, 19 (48) 11 (58) 1
No, 21 (52) 12 (57)TG, antithymocyte globulin.
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Enlimomab (Anti-IL-2R) for Steroid Refractory aGVHD 1139After analyzing the response according to the in-
olved organs, skin involvement improved in 22 of 30
ffected (73%), liver involvement in 15 of 30 patients
50%), and GI involvement in 21 of 34 patients (62%).
e found that all 6 patients without GI involvement
howed at least PR compared with 17 of 34 patients
50%) with GI involvement (P  .03; Table 4).
Those patients who developed aGVHD sooner
esponded better. Seven of 10 patients (70%) who
egan aGVHD before day 20 achieved a CR with
nlimomab compared with 8 of 30 patients (27%) who
egan aGVHD after day20 (P .02). However, this
ifference did not reach statistical signiﬁcance when
he overall response rate was analyzed: 7 of 10 patients
70%) in the former group responded compared with
6 of 30 (53%) in the latter group (P  .47).
Earlier start of enlimomab was associated with a
etter response: 15 of 21 patients (71%) who started
herapy within the ﬁrst 15 days of aGVHD obtained a
esponse compared with 8 of 19 patients (42%) who
egan enlimomab after day 15 (P  .06). In addition,
1 of 21 patients (52%) who began enlimomab before
5 days from onset of aGVHD achieved a CR com-
ared with only 4 of 19 (21%) who started this treat-
ent after day 15 after onset of aGVHD (P  .04).
Absolute lymphocyte count also appeared to have
relation to response to enlimomab. Median lympho-
yte count for all patients was 0.24  109/L. Median
ymphocyte counts before treatment for responders
nd nonresponders were 0.46  109/L and 0.22 
09/L, respectively (P  .007). Thus, responses were
ore frequently observed in patients with 0.24 
09/L (15 of 20 patients, 75%) than in those with
0.24  109/L (8 of 20, 40%; P  .05).
Other variables that had no effect on response rate
ere age, patient sex, donor age, donor sex, previous
se of ATG, HLA matching, GVHD prophylaxis,
onditioning regimens, or conditioning regimens
ased on total body irradiation.
Chronic GVHD (cGVHD) was observed in 18
f 23 evaluable patients (78%); 8 (35%) developed
imited disease and 10 (43%) developed extensive
GVHD.
Relapse of the underlying disease was observed in
able 4. Graft-versus-Host Disease Characteristics and Response
Organ n (%) Response, n (%)
3 (7.5) 3 (100)
 S 3 (7.5) 3 (100)
I 2 (5) 1 (50)
I  S 9 (22.5) 5 (55.6)
I  L 5 (12.5) 2 (40)
I  L  S 18 (45) 10 (52.6)
indicates liver; S, skin; GI, gastrointestinal.patients with acute myeloid leukemia 200 and 259 mays after enlimomab. Another patient, who had been
iagnosed with acute myeloid leukemia, developed
ost-transplantation lymphoproliferative syndrome 8
onths after enlimomab.
olerance
The drug was well tolerated without infusion-
elated adverse effects or late events that could be
irectly attributed to enlimomab.
nfections
As expected in these high-risk patients, infections
ere common. Thirty-seven of 40 patients had 1
nfectious event. Twenty-eight viral events were doc-
mented in 22 patients, mostly cytomegalovirus reac-
ivation (n  16) and herpes viral reactivation (n  5).
en fungal infections were diagnosed, with 7 cases of
robable or proved invasive aspergillosis. Forty-one
acterial infections were documented in 27 patients,
ostly catheter-related bacteriemias by coagulase-
egative staphylococci (n  21).
urvival
Median OS (since enlimomab was started) for the
ntire group was 58 days (range, 4-996 days), 14 days
or nonresponders (range, 4-52 days), and 294 days for
esponders (range, 24-996 days; P 	 .001). The prob-
bility of survival at 1 year for the entire group was
0%, with 0% for nonresponders versus 59% for
esponders (P 	 .0001; Figure 1).
The response achieved on day 15 predicted OS
median OS, 233 days [range, 24-549 days] for day-15
esponders versus 41 days [range, 19-996 days] for
ay-15 nonresponders). At median follow-up of 351
ays after therapy, OS was 73 
 12% for day-15
esponders versus 24 
 12% for day-15 nonre-
ponders (P  .02; Figure 2).
Twenty-six patients (65%) died at a median of 54
ays (range, 4-239 days) after the ﬁrst dose of enli-
omab. Causes of death are detailed in Table 1. Acute
VHD (n  15) and cGVHD (n  4) were the main
auses of death. The 30-, 90-, and 180-day cumulative
ncidences of nonrelapse mortality from start of enli-
Groups
Organs n (%) Response P
ot involved 6 (12.5) 6 (100) .03
volved 34 (27.5) 18 (45)GI n
GI inomab were 38% (95% conﬁdence interval, 25%-
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J. L. Pin˜ana et al.11406%), 56% (95% conﬁdence interval, 42%-74%), and
9% (95% conﬁdence interval, 45%-77%), respec-
ively.
ISCUSSION
Acute GVHD is the most common cause of mor-
idity and mortality after conventional and reduced
ntensity allogeneic hematopoietic stem cell transplan-
ations. Treatment with steroids leads to 	50% du-
able responses [3]. Salvage therapy after steroid fail-
re is not well established. ATG has been the most
ommon drug used in this setting, with responses
eing observed in 19%-56% of patients. Unfortu-
ately, survival after ATG treatment is very low, with
-year mortality as high as 90% [1]. Because current
nowledge attributes a special role to IL-2 in the
athology of aGVHD, we decided to treat steroid-
efractory aGVHD with enlimomab, an IL-2R inhib-
tor, in addition to CsA and prednisone.
Previous studies have shown activity of different
nti-IL-2Rs in the treatment of steroid-refractory
GVHD [11,12,14]. Anti-IL-2Rs differ in their mu-
ine or human origin, their pharmacokinetics, and their
fﬁnity to IL-2R and soluble IL-2R. These differences
ay partly explain the variable results published. An-
ther study that examined prednisone and daclizumab
17] as upfront therapy reported poorer results than with
rednisone alone. This may be related to a higher inci-
ence of relapse and higher infectious complications in
he study group, which may suggest that more intensive
mmunosuppression may not beneﬁt those patients with
ild aGVHD that could have responded to steroids
lone. Nevertheless, more detailed studies are needed to
igure 1. OS in patients who showed some degree of response with
reatment (solid line) and no response to treatment (dashed line).emonstrate this hypothesis. sOur series of 40 patients mostly included very
igh-risk patients. All but 2 had grade III-IV disease
nd most had been treated with ATG as second-line
reatment without response. Despite this, overall re-
ponse was 58%, with 38% CR and 20% PR. This
ncouraging response led to an OS of 30% at 1 year
59% for responders). We found that patients without
I involvement appeared to do better, with a 100%
esponse rate compared with the 50% response rate in
atients with GI involvement. A lower response in
atients with GI involvement has been reported re-
ently in a retrospectively multicenter [19] study,
hich be related to loss of enlimomab in stools, as
escribed by Herve et al [12] who found 40% of the
dministered anti-IL-2R in the stools of a patient with
evere diarrhea. This could support the need for
igher doses in those patients with GI aGVHD.
Responses were maintained in most patients, and
nly 5 patients (22%) relapsed after the initial re-
ponse. Although relapse of aGVHD was rare, 18 of
3 responders later developed cGVHD.
Patients who received enlimomab sooner ap-
eared to respond better. Similar results have been
bserved with ATG [20] and in a previous report of
nti-IL-2R [12]. We found that 70% of patients who
eveloped aGVHD before day 20 achieved a CR
ompared with only 27% of patients with aGVHD
hat appeared after day 20 (P  .02), but this con-
ideration must be interpreted with caution.
Response by day 15 predicted overall response and
urvival. Patients who showed some response by day
5 had a higher probability of response at the end of
reatment and, most importantly, showed improved
igure 2. OS according to responders (solid line) and nonre-
ponders (dashed line) on day 15.
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ost patients. In contrast, the absence of any response
y day 15 implies poor prognosis, and a second course
f enlimomab or another immunosuppressive agent
hould be offered to these patients.
Treatment with enlimomab was well tolerated, as
eported in other studies of anti-IL-2R treatment [11-
4]. Infections were common in our series, but most
atients had previously received ATG and/or MMF,
aking it difﬁcult to assess the contribution of each
gent. In the 6 patients who received enlimomab as
econd-line therapy after steroid failure, there were 3
acterial infections due to coagulase-negative staphy-
ococci, Enterococcus spp, and Clostridium difﬁcile and 1
o cytomegalovirus disease. Of note, in a study by
ahn et al [21] that compared the addition of anti-
L-2R to treatment with prednisone and CsA, no
ore infections were observed in patients who re-
eived anti-CD25 than in those who received pred-
isone and CsA alone.
In conclusion, enlimomab treatment of steroid-
efractory aGVHD offered promising results in high-
isk patients, with sustained response in many heavily
retreated patients. However, prospective randomized
tudies are needed to conﬁrm these observations.
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